SIDE EFFECTS
Gastrointestinal
Anorexia, malaise, abdominal discomfort or pain, dysphagia,
nausea, vomiting, and diarrhea have occurred. These are
more frequent with large doses or after one to three months
of continuous therapy. A few patients have had sudden
onset of profuse, watery diarrhea. Discontinue EDECRIN
if diarrhea is severe and do not give it again. Gastrointestinal
bleeding has occurred in some patients. Rarely, acute
pancreatitis has been reported.
Metabolic
Reversible hyperuricemia and acute gout have been reported.
Acute symptomatic hypoglycemia with convulsions occurred
in two uremic patients who received doses above those
recommended. Hyperglycemia has been reported. Rarely,
jaundice and abnormal liver function tests have been reported
in seriously ill patients receiving multiple drug therapy,
including EDECRIN.
Hematologic
Agranulocytosis or severe neutropenia has been reported
in a few critically ill patients also receiving agents
known to produce this effect. Thrombocytopenia has been
reported rarely. Henoch— Schänlein purpura
has been reported rarely in patients with rheumatic heart
disease receiving multiple drug therapy, including EDECRIN.
Special Senses (See WARNINGS)
Deafness, tinnitus and vertigo with a sense of fullness
in the ears, and blurred vision have occurred.
Central Nervous System
Headache, fatigue, apprehension, confusion.
Miscellaneous
Skin rash, fever, chills, hematuria. SODIUM EDECRIN occasionally
has caused local irritation and pain after intravenous
use.
DRUG INTERACTIONS
Lithium generally should not be given with diuretics
because they reduce its renal clearance and add a high
risk of lithium toxicity. Read circulars for lithium preparations
before use of such concomitant therapy.
EDECRIN may increase the ototoxic potential of other
drugs such as aminoglycoside and some cephalosporin antibiotics.
Their concurrent use should be avoided.
A number of drugs, including ethacrynic acid, have been
shown to displace warfarin from plasma protein; a reduction
in the usual anticoagulant dosage may be required in patients
receiving both drugs.
In some patients, the administration of a non- steroidal
antiinflammatory agent can reduce the diuretic, natriuretic,
and antihypertensive effects of loop, potassium- sparing
and thiazide diuretics. Therefore, when EDECRIN and non-
steroidal anti- inflammatory agents are used concomitantly,
the patient should be observed closely to determine if
the desired effect of the diuretic is obtained.
|
|
